47 results about "Chronic pain" patented technology

The invention provides an intelligent relieving system and method for phantom pain after breast resection based on biofeedback, develops a non-drug and non-invasive intelligent system, recognizes the phantom pain state in real time through multi-dimensional biofeedback, dynamically adjusts an intervention strategy, and solves the problems of high dependency and poor universality of a traditional method. Specifically, through multi-modal signal fusion, sEMG (surface electromyography), heart rate variability (HRV) and skin conductance (EDA) data are integrated, and the accuracy of magic pain recognition is improved. Through an adaptive algorithm, feedback parameters (such as electrical stimulation intensity and virtual reality scenes) are dynamically optimized based on an AI analgesia intervention model (such as LSTM), and personalized intervention is realized. According to the invention, a dynamic adjustment mechanism is integrated for magic pain for the first time, and the limitation of a traditional single intervention mode is broken through based on a self-adaptive adjustment strategy of a multi-modal signal. The occurrence rate of postoperative chronic pain is reduced, and consumption of medical resources is reduced. An intelligent tool is provided for nursing science, and the development of'precise nursing 'is promoted.

The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration.

The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. 5 The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration. 20 26 21 41 00 10 A ug 2 02 6 1 0 A u g 2 0 2 6 2 0 2 6 2 1 4 1 0 0

Provided herein are methods of nerve blockage, for example for treatment of obesity, heart failure, cardiovascular disease, muscle spasms, chronic pain, or urinary retention in a patient. The method comprises first heating a nerve above physiological temperature (e.g., 37° C. in a human), such as from 43° C. to 54° C. for a duration that leads to reversible nerve blockage as opposed to nerve damage. Second, reversible nerve blockage is produced by cooling the nerve below physiological temperature to a temperature in which reversible nerve blockage is achieved, for example from 15° C. to 30° C.

This invention provides a class of multi-target heteropeptides based on N-4-piperidinyl-N-phenylpropionamide analogs and neuropeptide FF. These heteropeptides use the small-molecule N-4-piperidinyl-N-phenylpropionamide and the polypeptide-structured neuropeptide FF as chemical templates. A series of peptide-small-molecule hybrid peptides are obtained by chemically coupling the pharmacophores of the N-4-piperidinyl-N-phenylpropionamide analog and the neuropeptide FF. In vivo pharmacological activity identification in animals shows that these heteropeptides possess analgesic activity without opioid-like side effects such as addiction and respiratory depression. Furthermore, compounds 1-4 and compounds 7-9 do not exhibit analgesic tolerance and can be used for long-term analgesic treatment of chronic pain. Therefore, these heteropeptides based on N-4-piperidinyl-N-phenylpropionamide analogs and neuropeptide FF can be used to prepare analgesic drugs.

The application provides an electroencephalogram pain positioning device, a training method and equipment, and constructs an electroencephalogram pain positioning device including a preprocessing module, a double-branch space-time coding backbone network, a mixed expert-weight decomposition low-rank adaptation module and a detection head. The double-branch space-time coding backbone network includes a coarse-grained branch for extracting low-frequency global features of electroencephalogram signals and a fine-grained branch for extracting high-frequency transient detail features of electroencephalogram signals. In this way, the transient high-frequency features of acute pain and the continuous low-frequency oscillation features of chronic pain can be captured at the same time, and the problem that a single scale network cannot consider the dynamic characteristics of different pain types is solved.

The invention discloses siRNA (small interfering ribonucleic acid) targeting SOX7, application of the siRNA in preparation of a medicine for treating chronic pain and the medicine, the small interfering RNA targeting the SOX7 gene comprises the SOX7 siRNA, the positive-sense strand sequence of the SOX7 siRNA is shown as SEQ.ID.NO.1, the antisense strand sequence of the SOX7 siRNA is shown as SEQ.ID.NO.2, and the small interfering RNA can target SOX7 genes of human and mice at the same time. The SOX7 siRNA is a group of siRNA for inhibiting the expression of the SOX7 gene, and siRNA targets are designed in a conserved region of the SOX7 gene and are located in a coding region. The expression of the SOX7 gene can be effectively reduced in vivo; by inhibiting the expression of the SOX7 gene, mechanical hyperalgesia generated by SNL induction can be effectively relieved, a foundation is laid for clinical treatment of sexual pain, and the application and popularization value is great.

The present invention relates to a sulfonylurea derivative and medical uses thereof, specifically relating to the sulfonylurea derivative shown in general formula (I), a preparation method thereof, a pharmaceutical composition containing same, and a use of same for treating diseases and disorders affected by neuronal damage, for example: cerebral stroke, brain damage, neuropathic pain, migraines, inflammatory pain, chronic pain, or depression. The definition of each group in the general formula (I) is the same as that in the description.

The invention relates to compounds, compositions, and methods for derepressing RE1 silencing transcription factor (REST) target genes are provided. In particular, a peptide having the sequence TEDLEPPEPPLPKEN (SEQ. ID NO: 1) and EDLEPPEPPLPK (SEQ. ID NO: 15), or the reversed sequences made of D-amino acids (retro inverted, RI) nekplppeppeldet (SEQ ID NO: 16) and kplppeppelde (SEQ ID NO: 17), are disclosed for inhibiting REST activity. The peptides are useful to treat, prevent, or ameliorate conditions such as traumatic brain injury, epilepsy, dementia, Huntington's Disease (HD), chronic pain, brain cancer (including glioblastoma multiforme), pancreatic cancer; diabetes, and peripheral nerve injury

The invention provides a coal mining screening mechanism which is characterized in that a heating unit is arranged on the surface of the side, attached to a joint, of a bearing cover, a mounting shell is fixed to the surface of the other side of the bearing cover, a driving assembly for forming one-way airflow at the joint hot compress position is arranged in the mounting shell, and the driving assembly absorbs moisture of air passing through the interior of the driving assembly; the two driving exercise assemblies are symmetrically arranged, and the two driving exercise assemblies are arranged on the two sides of the bearing cover and connected to the upper mounting cover and the lower mounting cover; the knee joint bends and stretches to drive the upper mounting cover and the lower mounting cover to rotate relatively, the driving exercise assembly provides resistance, and therefore the weight-bearing exercise effect is achieved. By constructing the constant-temperature drying and heating cavity and combining resistance-resistant exercise, hot compress and exercise collaboration is achieved, and the comfort, functionality and chronic pain relieving effect of knee joints are improved.

The invention provides an electroencephalogram pain positioning device, a training method and equipment, and constructs the electroencephalogram pain positioning device comprising a preprocessing module, a double-branch space-time coding backbone network, a hybrid expert-weight decomposition low-rank adaptation module and a detection head. The double-branch space-time coding backbone network comprises a coarse-grained branch used for extracting low-frequency global features of the electroencephalogram signals and a fine-grained branch used for extracting high-frequency transient detail features of the electroencephalogram signals, so that transient high-frequency features of acute pain and continuous low-frequency oscillation features of chronic pain can be captured at the same time, and the accuracy of the transient high-frequency features of the acute pain and the continuous low-frequency oscillation features of the chronic pain can be improved. The problem that a single-scale network cannot give consideration to dynamic characteristics of different pain types is solved.

The application discloses a kind of massage and whole body vibration training synergistic effect treatment chronic low back pain system, including patient information registration and management module, chronic pain assessment module, treatment effect assessment module, data analysis and feedback module, vibration training control terminal and massage treatment and guidance module;Through guiding patient to complete standardization waist action and record each posture under the pain score, determine main pain area in combination with Pareto analysis method, and utilize the score data in multiple treatments, construct mean and standard deviation model, and then realize the normal distribution fitting of pain change and curative effect determination;Massage and vibration training are linked through system, data intercommunication, realize the standardization of treatment process, intelligent and personalized intervention, effectively improve the rehabilitation efficiency of chronic low back pain patient.The application has the advantages of complete structure, scientific evaluation, precise intervention, etc., and is suitable for the popularization and application in the field of rehabilitation medicine and clinical physical therapy.

The invention provides sinomenine in preparation of a medicine for treating chronic pain of rheumatoid arthritis and application of the sinomenine in preparation of the medicine for treating the chronic pain of the rheumatoid arthritis, and aims at solving the problems that an existing medicine for resisting the rheumatoid arthritis is limited in action target spot and poor in treatment effect. The sinomenine takes a histamine receptor H1R on a nervous system dorsal root ganglion M1 type macrophage as the action target spot; the target spot is intervened to regulate and control polarization of macrophages, reduce expression of histamine H1R in M1 type macrophages and inhibit infiltration of the macrophages, so that chronic pain, including crymodynia, mechanical pain, heat pain and the like, of rheumatoid arthritis is effectively relieved; the sinomenine combined action target can improve pain and arthritis symptoms of a model mouse, reduce the level of inflammatory factors and inhibit LPS-induced macrophage migration and H1R expression, and the sinomenine pharmaceutical composition has various dosage forms, has unique action target and mechanism, has a remarkable treatment effect, and can be used for preparing medicines for treating chronic infectious diseases. The compound is expected to become a novel non-opioid anti-rheumatoid arthritis chronic pain medicine.

This invention discloses a novel class of monoacylglycerol lipase (MAGL) small molecule inhibitors, as well as their pharmaceutically acceptable compositions, methods of preparation, and uses. The MAGL small molecule inhibitors are represented by formula (I), having the specific substituents and definitions described herein. The disclosed MAGL small molecule inhibitors exhibit excellent MAGL enzyme inhibitory activity. This invention includes these compounds or their pharmaceutically acceptable compositions for the treatment and / or prevention of MAGL-related conditions such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colorectal cancer lesions, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or pain-related spasticity.

A transcutaneous magnetic stimulation (tMS) device is provided for modulating nerve function and chronic pain management, and includes a tMS stimulator, a control module in wired and powered communication with the tMS stimulator, and a portable electronic device in wireless communication with the control module to receive, generate and transmit feedback and control settings relating to a treatment session. The tMS stimulator may be a flexible figure-of-eight coil configured in different sizes and shapes to provide varying pulse and magnetic field strengths for mobile, home, or clinical uses, and also include guidance tools and measurement sensors to aid in positioning and directing the tMS stimulator to a target area for treatment.

The present invention relates to epiregulin antibodies, compositions comprising the same, and methods of making and / or using the antibodies and / or compositions thereof for chronic pain disorders such as chronic osteoarthritis pain, or chronic diabetic peripheral neuropathy pain, or chronic low back pain.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for promoting menstruation and removing stasis, an external preparation and application. The traditional Chinese medicine composition consists of teasel root, lycopodium clavatum, frankincense, myrrh, divaricate saposhnikovia root, pseudo-ginseng, turmeric, cinnamon, litsea cubeba, ligusticum wallichii, gardenia, mulberry twig, lotus leaf, rheum officinale, dragon's blood, salvia miltiorrhiza, safflower, folium artemisiae argyi and mint. The traditional Chinese medicine composition for promoting menstruation and removing stasis is reasonable in compatibility, has an excellent treatment effect on wind-cold-dampness arthralgia, and is suitable for patients with symptoms such as scapulohumeral periarthritis, cervical spondylosis, lumbocrural pain, muscle and joint pain, rheumatic arthritis, rheumatoid arthritis and gouty arthritis. A specific natural penetrant composition and a traditional Chinese medicine composition are selected to be prepared into an external dosage form, the medicine can be promoted to enter a target organ or tissue through a physiological barrier, the medicine can directly act on a focus, the effect is quick, the efficacy is lasting, the use is convenient, the patient compliance is good, no toxic or side effect exists, and a new choice of an external transdermal agent is provided for clinical treatment of chronic pain.

The present disclosure relates to compositions, methods and processes for the design, preparation, manufacture, use and / or formulation of modulatory polynucleotides, e.g., polynucleotides encoding small interfering RNA (siRNA) molecules which target the transcript encoding the alpha (α) subunit of voltage-gated sodium channel (Nav) 1.7 to treat chronic neuropathic pain. In some embodiments, nucleic acid sequences encoding the siRNA molecules are inserted into recombinant adeno-associated virus (AAV) vectors. Methods for using the siRNA molecules to inhibit the expression of mutated or wild-type Nav1.7 in a subject with chronic pain (e.g., chronic neuropathic pain) are also disclosed.

The invention provides a hot compress device and method for chronic pain of old people based on internal medicine of traditional Chinese medicine, and the method comprises the steps: carrying out the correlation analysis of the surface temperature and the redness state of a hot compress part in a preheating process, and obtaining the sensitivity of a target hot compress part of the old people to the temperature; further determining a skin stress index when the target hot-compress part of the old person is subjected to hot compress; determining a temperature difference constraint condition between the hot compress part of the target old person and the hot compress temperature according to the rising gradient and the falling gradient of the surface temperature of the hot compress part, and further determining an out-of-control interval of the surface temperature when the hot compress device heats the hot compress part of the target old person; according to the skin stress index and the out-of-control interval, determining the heating gradient when the hot compress device performs hot compress on the target old people, and adjusting the temperature when the hot compress device heats the hot compress part of the target old people according to the heating gradient. By the adoption of the scheme, gradient control can be conducted on heating of the hot compress device in combination with a dynamic sensing mechanism of the skin of the old people for the temperature.

The application method comprises the steps that the traditional Chinese medicine bag is prepared, the traditional Chinese medicine bag is provided with a three-layer structure, the outer layer of the traditional Chinese medicine bag is coated with an adjustable opening structure, the adjustable opening structure is used for controlling the drug effect release area, the traditional Chinese medicine bag is flatly laid on an electric blanket with the set temperature range being 40 DEG C to 60 DEG C, and the traditional Chinese medicine bag is placed on the electric blanket; the electric blanket is electrified to heat, a temperature curve is set according to treatment requirements, and effective components of three layers of medicinal materials of the traditional Chinese medicine bag are sequentially activated under the warm action, so that anti-inflammatory components are preferentially released, meridian dredging components are gradually released, and blood activating components are slowly released in the later period. Therefore, the sustainable design of replacing the medicine core breaks through the limitations of high-frequency consumption, high cost and non-environmental protection of a traditional Chinese medicine bag, the use convenience and economic adaptability are remarkably improved, and a low-cost, high-efficiency and intelligent medicine-heat synergistic treatment solution is provided for the scenes of chronic pain, sub-health conditioning and the like.

The invention belongs to the field of medical instruments, and relates to a semi-automatic minimally invasive graft tendon taking device for articular ligament reconstruction, which comprises a control handle and a hollow tendon taking rod, and the hollow tendon taking rod is connected with the end part of the control handle; a first through groove is formed in the middle of the control handle, and a push rod penetrates through the first through groove; a cutting edge is coaxially arranged in the hollow tendon taking rod; one end of the cutting edge abuts against the inner side wall of one end of the control handle and is connected with the push rod, and the other end of the cutting edge is a bendable end which is located at the tendon taking end of the hollow tendon taking rod. A cutting groove is formed in the inner side wall of the tendon taking end, and a guide curved surface is arranged opposite to the cutting groove; the push rod can drive the cutting edge to move towards the tendon taking end, so that the bendable end of the cutting edge is bent along the guide curved surface and then is meshed with the cutting groove, and the taken tendon is cut off. By means of the device, directional cutting can be achieved, then the obtained tendon can be completely stripped, and chronic pain caused by residues is prevented.

The present disclosure relates to the field of diseases caused by reduced synaptic inhibition, preferably those caused by reduced activity of potassium (K) / chlorine (Cl) cotransporter (KCC2). The present disclosure relates to oligonucleotides and their use in RNA editing methods that target the target adenosine in the SLC12A5 precursor mRNA encoding KCC2 or in the codon encoding the phosphorylation site in the mRNA, preferably the adenosine in the codon encoding threonine at position 1007 of the KCC2b isoform. Through editing, threonine is replaced by alanine, so that phosphorylation sites are removed, and the activity of KCC2 protein in the process of recovering GABA (gamma-aminobutyric acid) capable of inhibiting tension is increased. The disclosure further relates to oligonucleotides for the treatment of chronic pain and epilepsy.

The application belongs to the technical field of short peptide medicine, and specifically discloses a Maged1 competitive short peptide and application thereof.The Maged1 competitive short peptide is short peptide MP1 or short peptide MP2, and the amino acid sequence is shown as SEQ ID No.1 or SEQ ID No.2.Experiments prove that the Maged1 competitive short peptide can compete with Maged1 to combine with P2X3 receptors, thereby inhibiting the activation of Maged1 on P2X3 receptors, and has a good clinical application prospect in the treatment of chronic pain.

The invention relates to the technical field of medical information, and discloses a method for predicting a surgical pain model program result based on an internet hospital, and the method comprises the steps: 1, collecting the preoperative data of a patient, carrying out the postoperative pain risk prediction based on an artificial intelligence model, and generating a postoperative pain prediction result; 2, according to the postoperative pain prediction result in the step 1, an intraoperative analgesia scheme is formulated, and adjustment is carried out based on real-time physiological parameters of a patient in the operation process; 3, according to the intraoperative data in the step 2, a patient postoperative pain management file is established, a postoperative patient wears intelligent wearable equipment, physiological data are monitored in real time, and a personalized multi-mode analgesia scheme is formulated. According to the method, the multi-layer neural network is combined with the Bayesian reasoning mixed technology, accurate prediction of postoperative acute and chronic pain is achieved, compared with an existing single model, the data fusion and prediction accuracy is greatly improved, and the problem that in a traditional scheme, individual difference capture is insufficient is solved.

The present disclosure relates to peptide compositions and methods for treating an inflammatory condition such as ocular inflammation, retinal inflammation, dry eye, uveitis, allergic conjunctivitis, and inflammation resulting from nerve injury or nerve degeneration. The peptide compositions disclosed herein can also be used for treating pain such as neuropathic pain, ocular pain, chronic pain, pain resulting from chemotherapy or radiation, pain resulting from nerve injury or nerve degeneration, and pain resulting from an inflammatory condition, dysesthesia, or allodynia.

The invention provides siRNA (small interfering Ribonucleic Acid) targeting SMAD1 and application of siRNA in neuropathic pain treatment medicines, relates to the technical field of biomedicine, and has the technical key points that the application of SMAD1 as a treatment target in preparation of the medicines for treating neuropathic pain is provided, and three groups of chemically modified nucleic acid siRNA molecules targeting SMAD1 genes are provided based on the application. The three groups can effectively reduce the expression of the SMAD1 gene; the siRNA molecules in the second group have the optimal effect of interfering SMAD1 gene expression, can effectively relieve SNI-induced chronic mechanical hyperalgesia, can also reduce expression of pain-related genes CRH, lays a foundation for clinical treatment of chronic pain, and has great application and popularization values and social values.

The invention discloses a novel monoacylglycerol lipase (MAGL) small-molecule inhibitor as well as a pharmaceutical composition, a preparation method and application thereof. The MAGL small-molecule inhibitor is represented by a formula (I), wherein specific substituents and definitions are described in the specification. The MAGL small molecule inhibitor disclosed by the invention shows excellent MAGL enzyme inhibition activity. The present invention includes these compounds or pharmaceutical compositions thereof for use in the treatment and / or prevention of MAGL-related conditions, in particular, the present invention relates to compounds of general formula (I), which can be used to treat various conditions such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colorectal cancer lesions, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or pain-related spasm.

The application discloses a preparation method and application of jujuboside. The application develops an enrichment and purification preparation method of jujuboside with high purity and suitable for mass production, and the jujuboside prepared by using the method has the advantages of high product purity, short purification steps, easy scale-up production, less time consumption and the like. The application firstly finds that the jujuboside has significant inhibitory activity on a TRPV1 ion channel, can be used as a TRPV1 ion channel inhibitor, and has anti-inflammatory activity, and the jujuboside has important application prospects for developing drugs for treating chronic pain, inflammation and hyperlipidemia and the like. The jujuboside is used as an active ingredient to prepare cosmetics with anti-inflammatory, analgesic and soothing effects, and also has important application value in cosmetic development.

The application relates to application of protocatechuic acid as an inhibitor of a calcium ion channel, belongs to the field of medicine, and also provides use of protocatechuic acid in preparation of drugs for treating cardiovascular diseases, coronary heart disease, atherosclerosis, end-stage renal failure, nervous diseases, chronic pain, acute pain or inflammatory diseases, proves that the protocatechuic acid can inhibit the calcium ion channel, especially a TRPC ion channel, and expands the use of the protocatechuic acid.